查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1845717

全球元基因组定序市场规模（依工作流程、产品/服务、技术、应用、区域覆盖和预测）

Global Metagenomic Sequencing Market Size By Workflow, By Product And Services, By Technology, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

宏基因体定序市场规模及预测

2024 年宏基因体定序市场规模为 10.4998 亿美元，预计到 2032 年将达到 16.4863 亿美元，2026 年至 2032 年的复合年增长率为 6.40%。

元基因组定序市场是一个商业领域，涵盖用于对环境样本中的遗传物质进行高通量分析的产品、服务和技术。该市场提供用于研究整个微生物群落（而非单一生物体）的集体基因组的工具和解决方案。

该市场的主要组成部分包括：

设备：定序设备及相关硬体

试剂和耗材：用于样品处理和文库製备的试剂套件和化学试剂。

定序服务：为没有自己的定序设备的实验室和研究人员提供外包服务。

生物资讯软体和数据分析：处理、分析和解释元基因组定序产生的庞大数据集的计算工具。

这个市场是由对了解微生物群落于各个领域的作用的需求不断增长所驱动的，例如：

临床诊断：临床诊断：识别病原体并描述人类微生物组以了解其在健康和疾病中的作用。

环境监测：评估土壤、水和其他生态系中的微多样性。

药物发现：发现用于製药和生物技术应用的新基因、酵素和代谢途径。

透过研究与农业植物相关的微生物组来改善土壤健康和作物产量。

这个市场的特点是技术不断进步，例如开发更有效率、更实惠的定序平台以及整合人工智慧和机器学习来处理复杂的数据分析。

全球宏基因体定序市场驱动因素

元基因组组定序市场正在经历快速扩张，这主要得益于几个关键因素。这项革命性的技术能够对样本中的整个微生物群落进行全面分析，正成为许多科学和医学领域不可或缺的技术。对于希望在这个快速成长的市场中获利的相关人员来说，了解这些关键驱动因素至关重要。

个人化医疗应用日益增长：蓬勃发展的个人化医疗领域是元基因组定序市场发展的强大催化剂。随着医疗保健向高度个人化治疗方向发展，了解患者独特的微生物组至关重要。宏基因定序为人类微生物组提供了前所未有的洞察，揭示了微生物群落如何与宿主遗传、生活方式和疾病状态相互作用。这种深入的理解有助于制定个人化治疗策略，从优化药物剂量到设计益生菌干预措施。例如，透过总体基因体学分析个体的肠道菌群可以预测患者对特定药物的反应，或指导慢性疾病的饮食建议。精准医疗趋势旨在客製化治疗方法，以实现最大疗效和最小副作用，这将继续推动对全面基因组学和元基因组分析的需求，使这项技术成为个人化医疗的前沿。

感染疾病疫情日益严峻：感染疾病这一持续存在的全球性挑战是宏基因组定序市场的另一个关键驱动力。传统的诊断方法通常耗时耗力、成本高昂，且在识别新型或罕见病原体方面能力有限。然而，元基因组定序提供了一种快速、公正、全面的病原体检测方法，为病原体检测提供了强有力的解决方案。透过对样本中的所有基因进行定序，可以同时识别细菌、病毒、真菌和寄生虫，即使是那些难以培养或先前未鑑定的病原体也能被识别。这种能力在集体爆发调查、病源识别和抗生素抗药性模式监测中至关重要。为了对抗新兴感染疾病并改善公共卫生状况，人们迫切需要更快、更准确、更广泛的诊断工具，这导致全球对元基因组定序技术的需求持续增长。

基因组学研究投资不断增加：全球基因组学研究持续不断的大量投资正在显着增强宏基因组定序市场。各国政府、学术机构和私人生物技术公司正在向旨在揭示基因组和微生物组复杂性的计划投入大量资金。这些投资正在推动技术创新，从而开发出更有效率、更准确、更具成本效益的定序平台和用于数据分析的先进生物资讯学工具。致力于理解微生物多样性、宿主-微生物相互作用以及微生物群落在各种生态系统中的功能作用的研究与元基因组测序的日益普及直接相关。随着研究人员发现新的应用并透过基因组学洞察加深对生物学的理解，对先进定序能力的需求只会日益增长，为元基因组组定序市场的持续扩张和发展创造了肥沃的土壤。

限制全球元基因组定序市场的因素

儘管全球宏基因组定序市场有望实现显着成长，但它面临一些关键限制因素，阻碍了其广泛应用和市场发展。从高成本到复杂的数据分析，这些限制因素可能会影响市场的发展轨迹，尤其是在新兴经济体和研发投入较小的地区。了解这些挑战对于相关人员有效驾驭市场，以及创新者开发克服这些障碍的解决方案至关重要。

高成本和预算限制：元基因组定序市场的一个主要限制因素是该技术的高成本。这不仅包括定序仪器本身的价格（可能高达数十万美元），还包括样品製备、试剂和专用耗材的大量费用。 Illumina 的旗舰平台 NovaSeq 5000 和 6000 的售价分别为 850,000 美元和 985,000 美元，对于许多学术研究机构（尤其是开发中国家）来说，这笔投资过高。虽然每个定序基因组的成本随着时间的推移而下降，但完整的元基因组分析计划（包括定序、数据分析和专家人力）所需的总预算仍然是限制采用和市场成长的重大障碍。

复杂的数据分析与生物资讯学挑战：元基因组定序会产生大量数据，为分析与解读带来巨大挑战。数据通常来自庞大而复杂的微生物群落，而许多生物体在现有资料库中缺乏参考基因组。这使得对现有微生物进行准确分类和定量分析变得困难。缺乏标准化的资料管理和分析工具也是一个主要障碍。研究人员和临床医生需要先进的生物资讯学专业知识来处理这些数据，包括过滤原始数据、组装片段化的基因组（或「箱」）以及为新发现的基因分配功能。管理如此复杂的工作流程需要专业且高技能的专家，而此类人才的短缺是一个主要限制因素，可能会延迟研究和临床应用。

缺乏标准化和可重复性：另一个主要限制是宏基因组学工作流程缺乏标准化。从初始样本采集和DNA提取到定序通讯协定和数据分析流程，差异性可能导致结果不一致且不可重复。例如，不同的DNA萃取方法可能产生偏差，导致某些微生物的裂解效率更高或更低，从而扭曲最终的群落结构。缺乏标准化通讯协定为比较不同研究、实验室甚至不同大洲的结果带来了挑战。如果没有可靠且可重复的方法，就很难建立明确的品质基准，这使得元基因组组定序在临床诊断中的应用变得复杂，因为一致性对于患者照护和监管核准至关重要。

监管和伦理障碍：随着宏基因定序从研究工具转向临床诊断，它面临日益严格的监管和伦理审查。在临床环境中，用于诊断疾病的技术必须经过严格的验证和监管核准，以确保安全性和有效性。这一过程耗时耗力，可能会延迟新型元基因组检测的商业化和临床应用。此外，伦理问题也随之而来，尤其是在处理人类微生物组时。资料隐私、知情同意以及个人微生物组图谱的潜在滥用等问题错综复杂，需要明确的指导方针。缺乏强有力的法律规范来应对这些问题，严重限制了市场成长，尤其是在个人化医疗和公共卫生相关的应用领域。

目录

第一章 引言

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第二章调查方法

  • 资料探勘
  • 二次调查
  • 初步调查
  • 专家建议
  • 品质检查
  • 最终审核
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 资料来源

第三章执行摘要

  • 全球元基因组定序市场概览
  • 全球元基因组定序市场估计与预测
  • 全球沼气流量计生态测绘
  • 竞争分析：漏斗图
  • 全球元基因组定序市场绝对商机
  • 全球元基因组定序市场吸引力分析（按地区）
  • 全球元基因组定序市场吸引力分析（按工作流程）
  • 全球元基因组定序市场吸引力分析（按产品和服务）
  • 全球元基因组定序市场吸引力分析（按技术）
  • 全球元基因组定序市场吸引力分析（按应用）
  • 全球元基因组定序市场区域分析
  • 全球元基因组定序市场（依工作流程）
  • 全球元基因组定序市场（按产品和服务）
  • 全球元基因组定序市场（按技术）
  • 全球元基因组定序市场（按应用）
  • EEEE 的全球元基因组定序市场
  • 全球元基因组定序市场（按地区）
  • 未来市场机会

第四章 市场展望

  • 全球元基因组定序市场的转型
  • 全球元基因组定序市场展望
  • 市场驱动因素
  • 市场限制
  • 市场趋势
  • 市场机会
  • 波特五力分析
    • 新进入者的威胁
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 现有竞争对手之间的敌意
  • 价值链分析
  • 定价分析
  • 宏观经济分析

第五章：工作流程市场

  • 概述
  • 全球元基因组定序市场：依工作流程的Basis Point Share（bps）分析
  • 样品处理和文库製备
  • 顺序
  • 数据处理与分析

第六章 产品/服务市场

  • 概述
  • 全球元基因组定序市场：按产品和服务Basis Point Share（bps）分析
  • 试剂和耗材
  • 装置
  • 服务

第七章 按技术分類的市场

  • 概述
  • 全球元基因组定序市场：依技术Basis Point Share（bps）分析
  • 鸟枪法宏基因组定序
  • 16s rRNA测序
  • 宏转录组学
  • 全基因组定序与从头组装

第 8 章 按应用分類的市场

  • 概述
  • 全球元基因组定序市场：按应用Basis Point Share（bps）分析
  • 药物研发
  • 临床诊断
  • 土壤微生物组
  • 生态系与环境

第九章 区域市场

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第十章 竞争格局

  • 概述
  • 主要发展策略
  • 公司的地理分布
  • 王牌矩阵
    • 积极的
    • 前线
    • 新兴
    • 创新者

第十一章：公司简介

  • OVERVIEW
  • ILLUMINA INC
  • THERMO FISHER SCIENTIFIC INC
  • QIAGEN NV
  • PERKINELMER
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • BGI GROUP
  • MACROGEN INC
  • GENEWIZ
  • EUROFINS SCIENTIFIC
  • NOVOGENE CORPORATION
Product Code: 5917

Metagenomic Sequencing Market Size And Forecast

Metagenomic Sequencing Market size was valued at USD 1049.98 Million in 2024 and is projected to reach USD 1648.63 Million by 2032, growing at a CAGR of 6.40% from 2026 to 2032.

The Metagenomic Sequencing Market is defined as the commercial sector encompassing the products, services, and technologies used for the high-throughput analysis of genetic material from environmental samples. This market provides tools and solutions for studying the collective genomes of entire microbial communities, rather than individual organisms.

Key components of this market include:

Instruments: Sequencing machines and related hardware.

Reagents & Consumables: Kits and chemical reagents for sample processing and library preparation.

Sequencing Services: Outsourced services for labs and researchers who do not have their own sequencing equipment.

Bioinformatics Software & Data Analysis: Computational tools for processing, analyzing, and interpreting the massive datasets generated by metagenomic sequencing.

The market is driven by the growing demand for understanding the role of microbial communities in various fields, including:

Clinical Diagnostics: Identifying pathogens and analyzing the human microbiome to understand its role in health and disease.

Environmental Monitoring: Assessing microbial diversity in soil, water, and other ecosystems.

Drug Discovery: Discovering new genes, enzymes, and metabolic pathways for pharmaceutical and biotechnological applications.

Agriculture: Improving soil health and crop yield through the study of plant-associated microbiomes.

The market is characterized by ongoing technological advancements, such as the development of more efficient and affordable sequencing platforms, and the integration of artificial intelligence and machine learning to handle complex data analysis.

Global Metagenomic Sequencing Market Drivers

The metagenomic sequencing market is experiencing rapid expansion, propelled by several significant factors. This revolutionary technology, which allows for the comprehensive analysis of entire microbial communities within a sample, is becoming indispensable across diverse scientific and medical disciplines. Understanding these key drivers is crucial for stakeholders looking to capitalize on this burgeoning market.

Growing Applications in Personalized Medicine: The burgeoning field of personalized medicine stands as a powerful catalyst for the metagenomic sequencing market. As healthcare shifts towards highly individualized treatments, the ability to understand a patient's unique microbial landscape becomes paramount. Metagenomic sequencing provides unprecedented insights into the human microbiome, revealing how microbial communities interact with host genetics, lifestyle, and disease states. This deep understanding enables the development of tailored therapeutic strategies, from optimizing drug dosages to designing probiotic interventions. For instance, analyzing an individual's gut microbiome through metagenomics can predict their response to certain medications or guide dietary recommendations for chronic conditions. The trend towards precision healthcare, where treatments are customized for maximum efficacy and minimal side effects, will continue to drive the demand for comprehensive genomic and metagenomic profiling, positioning this technology at the forefront of personalized medicine.

Increasing Prevalence of Infectious Diseases: The persistent global challenge of infectious diseases is another critical driver for the metagenomic sequencing market. Traditional diagnostic methods can often be slow, expensive, and limited in their ability to identify novel or uncommon pathogens. Metagenomic sequencing, however, offers a powerful solution by providing a rapid, unbiased, and comprehensive method for pathogen detection. By sequencing all genetic material in a sample, it can identify bacteria, viruses, fungi, and parasites simultaneously, even those that are difficult to culture or have not been previously characterized. This capability is invaluable in outbreak investigations, identifying the source of infections, and monitoring antimicrobial resistance patterns. The urgent need for faster, more accurate, and broader-spectrum diagnostic tools to combat emerging infectious diseases and improve public health outcomes ensures a sustained and growing demand for metagenomic sequencing technologies worldwide.

Rising Investments in Genomics Research: Substantial and sustained investments in genomics research globally are significantly bolstering the metagenomic sequencing market. Governments, academic institutions, and private biotech firms are channeling considerable funding into projects aimed at unraveling the complexities of genomes and microbiomes. These investments fuel technological innovation, leading to the development of more efficient, accurate, and cost-effective sequencing platforms, as well as sophisticated bioinformatics tools for data analysis. Research initiatives focused on understanding microbial diversity, host-microbe interactions, and the functional roles of microbial communities in various ecosystems directly translate into an increased adoption of metagenomic sequencing. As researchers uncover new applications and deepen our understanding of biology through genomic insights, the demand for advanced sequencing capabilities will only intensify, creating a fertile ground for the continued expansion and evolution of the metagenomic sequencing market.

Global Metagenomic Sequencing Market Restraints

The global metagenomic sequencing market, while experiencing significant growth, faces several key restraints that challenge its widespread adoption and development. These limitations, from high costs to complex data analysis, can impact the market's trajectory, particularly in developing economies and for smaller research labs. Understanding these challenges is crucial for stakeholders to navigate the market effectively and for innovators to develop solutions that overcome these hurdles.

High Costs and Budgetary Constraints: A primary restraint of the metagenomic sequencing market is the high cost associated with the technology. This isn't just about the price of the sequencing instruments themselves, which can run into the hundreds of thousands of dollars, but also the significant expenses involved in sample preparation, reagents, and specialized consumables. The NovaSeq 5000 and 6000, two of Illumina's leading platforms, can be priced at $850,000 and $985,000, respectively, making them a prohibitive investment for many academic and research institutions, particularly in developing countries. Even as the cost per sequenced genome has decreased over time, the overall budget required for a complete metagenomic project including sequencing, data analysis, and expert personnel remains a major barrier that limits adoption and market growth.

Complex Data Analysis and Bioinformatics Challenges: Metagenomic sequencing generates an enormous volume of data, creating a significant challenge for analysis and interpretation. The data is often from a vast and complex microbial community, with many organisms lacking a reference genome in existing databases. This makes it difficult to accurately classify and quantify the microbes present. The lack of standardized data management and analytical tools also presents a major hurdle. Researchers and clinicians need a high level of expertise in bioinformatics to handle the data, which includes filtering raw reads, assembling fragmented genomes (or "bins"), and assigning functions to newly discovered genes. The need for specialized, highly skilled professionals to manage these complex workflows is a major constraint, as a shortage of such talent can slow down research and clinical implementation.

Lack of Standardization and Reproducibility: Another significant restraint is the lack of standardization across the entire metagenomic workflow. From the initial sample collection and DNA extraction to sequencing protocols and data analysis pipelines, variations can lead to inconsistent and irreproducible results. For example, different DNA extraction methods may introduce biases by being more or less efficient at lysing certain types of microbes, thus skewing the final community profile. This lack of standardized protocols creates a challenge for comparing results between different studies, laboratories, and even continents. Without reliable and reproducible methods, it becomes difficult to establish a clear benchmark for quality and to use metagenomic sequencing for clinical diagnostics, where consistency is paramount for patient care and regulatory approval.

Regulatory and Ethical Hurdles: As metagenomic sequencing moves from a research tool to a clinical diagnostic method, it faces increasing regulatory and ethical scrutiny. In clinical settings, technologies used for diagnosing diseases must undergo rigorous validation and regulatory approval to ensure they are safe and effective. This process can be lengthy and expensive, slowing down the commercialization and clinical adoption of new metagenomic tests. Furthermore, ethical concerns arise, particularly when dealing with the human microbiome. Questions about data privacy, informed consent, and the potential misuse of an individual's microbiome profile are complex and require clear guidelines. The absence of a robust regulatory framework to address these issues is a significant restraint on the market's growth, especially in applications related to personalized medicine and public health.

Global Metagenomic Sequencing Market: Segmentation Analysis

The Global Metagenomic Sequencing Market is Segmented on the basis of Workflow, Product and Services, Technology, Application, And Geography.

Metagenomic Sequencing Market, By Workflow

Sample Processing & Library Preparation

Sequencing

Data Processing & Analysis

Based on Workflow, the Metagenomic Sequencing Market is segmented into Sample Processing & Library Preparation, Sequencing, and Data Processing & Analysis. At VMR, we observe that the Sequencing subsegment holds a dominant position, accounting for a significant market share, with estimates often placing it at over 50% of the total revenue contribution. This dominance is driven by the continuous technological advancements in Next-Generation Sequencing (NGS) platforms from key players such as Illumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies. The dramatic decline in sequencing costs, along with a significant increase in throughput and accuracy, has made large-scale metagenomic projects feasible and highly attractive for a wide range of applications. The demand for sequencing is particularly strong in North America, a region that leads the market due to robust R&D spending, the presence of major biotech companies and academic institutions, and a strong focus on precision medicine and drug discovery. The Sequencing subsegment is the core engine of the market, as it generates the massive data sets required for all downstream analysis and is essential for key end-users in drug discovery and clinical diagnostics.

The Sample Processing & Library Preparation subsegment is the second most dominant in the workflow, with a crucial role as the foundational step of any metagenomic project. Its growth is fueled by the need for specialized kits and reagents that minimize contamination and ensure high-quality, representative DNA from complex samples like soil, water, and the human gut. This segment's importance is underscored by the fact that the quality of the raw data is directly dependent on the initial sample preparation, making it a critical bottleneck and a focus for innovation. The growth of this subsegment is supported by the increasing number of research projects and the expansion of metagenomic applications in new industries, which require tailored protocols. Finally, the Data Processing & Analysis subsegment, while currently smaller in revenue, is projected to be the fastest-growing component of the workflow. The exponential volume of data generated by modern sequencers has created a burgeoning demand for advanced bioinformatics software, AI-driven analytical tools, and cloud-based platforms to handle the complexity of microbial community data. The future potential of this subsegment is immense, as it directly addresses the critical challenges of data interpretation and is essential for extracting actionable insights from the raw sequencing data for end-users in academia, pharmaceuticals, and environmental science.

Metagenomic Sequencing Market, By Product and Services

Reagents & Consumables

Instruments

Services

Based on Product and Services, the Metagenomic Sequencing Market is segmented into Reagents & Consumables, Instruments, Services. At VMR, we observe that the Reagents & Consumables subsegment holds the dominant market share, often exceeding 55%, due to its fundamental and recurring role in nearly every sequencing project. This dominance is driven by the consistent need for a wide array of kits, enzymes, and other chemical agents necessary for DNA/RNA extraction, library preparation, and sequencing on a per-run basis. The segment is further propelled by the increasing adoption of high-throughput sequencing in key industries such as clinical diagnostics and drug discovery, particularly in North America, which is the leading regional market due to significant R&D investments and the presence of major life sciences companies. Technological advancements, including the development of more efficient and cost-effective library preparation kits, are a key market trend supporting this subsegment's growth.

The second most dominant subsegment, Instruments, represents the essential hardware platforms like next-generation sequencers (NGS) that enable the entire workflow. Although a high-value, one-time capital expenditure, this segment is a significant revenue contributor, with its growth supported by continuous technological innovation, which has led to a dramatic decline in the cost per run, making sequencing more accessible. The Services subsegment, while smaller in market share, is the fastest-growing component of the market, with a projected CAGR of over 17%. Its role is to provide specialized sequencing, data analysis, and interpretation to researchers, hospitals, and companies that lack the internal infrastructure or bioinformatic expertise. This subsegment's expansion is fueled by the sheer volume of data generated by modern sequencers and the growing complexity of bioinformatics, highlighting a future market shift toward expert-driven data solutions.

Metagenomic Sequencing Market, By Technology

Shotgun Metagenomic Sequencing

16S rRNA Sequencing

Metatranscriptomics

Whole-genome Sequencing & De Novo Assembly

Based on Technology, the Metagenomic Sequencing Market is segmented into Shotgun Metagenomic Sequencing, 16S rRNA Sequencing, Metatranscriptomics, and Whole-genome Sequencing & De Novo Assembly. At VMR, we observe that Shotgun Metagenomic Sequencing is the dominant technology, capturing a significant market share, with some reports indicating its revenue contribution is over 40%. Its dominance stems from its ability to provide a comprehensive, unbiased view of an entire microbial community, sequencing all DNA in a sample, including bacteria, viruses, fungi, and archaea. This holistic approach is a key driver for its adoption in a wide array of applications, from human microbiome analysis to environmental studies and infectious disease surveillance. The decline in sequencing costs, coupled with advancements in bioinformatics tools and AI-driven data analysis, has made this powerful technology more accessible, fueling its growth, particularly in North America, where robust R&D funding and a strong presence of biotech and pharmaceutical companies drive high demand.

The second most dominant subsegment is 16S rRNA Sequencing, which, while less comprehensive than shotgun sequencing, remains highly popular due to its cost-effectiveness and well-established protocols for taxonomic profiling. It targets a specific, conserved gene region in bacteria and archaea, making it ideal for studies focused on microbial diversity and community composition. This technology continues to be a staple in academic research and is often used for preliminary microbiome studies before a deeper, more expensive shotgun approach is considered. The remaining subsegments, including Metatranscriptomics and Whole-genome Sequencing & De Novo Assembly, occupy a more niche yet rapidly expanding role. Metatranscriptomics focuses on sequencing RNA to understand the active gene expression and functional potential of microbial communities, while Whole-genome Sequencing & De Novo Assembly is a specialized method used to reconstruct complete microbial genomes from complex samples, particularly for novel, unculturable organisms. These technologies represent the future of the market, addressing more complex research questions and supporting advanced applications in drug discovery and novel pathogen identification.

Metagenomic Sequencing Market, By Application

Drug Discovery

Clinical Diagnostics

Soil Microbiome

Ecological and Environmental

Based on Application, the Metagenomic Sequencing Market is segmented into Drug Discovery, Clinical Diagnostics, Soil Microbiome, Ecological and Environmental. At VMR, we observe that the Drug Discovery subsegment is currently the dominant application, holding a significant market share and driving substantial revenue. This dominance is propelled by several key market drivers and industry trends. Pharmaceutical and biotechnology companies are increasingly leveraging metagenomic sequencing to explore the vast, untapped microbial biodiversity for the discovery of novel drug targets, enzymes, and bioactive compounds, particularly for addressing antimicrobial resistance and developing personalized medicines. The adoption is high in North America, which benefits from robust R&D expenditure, extensive government and private funding for genomic research, and the presence of major industry players. This trend is further fueled by the integration of AI and machine learning for bioinformatics, which helps analyze the massive datasets generated by sequencing, accelerating the drug development pipeline.

The Clinical Diagnostics subsegment holds the second-largest position, experiencing rapid growth. This segment's expansion is driven by the rising demand for quick and accurate pathogen detection and diagnosis of infectious diseases. Metagenomics offers a powerful alternative to traditional culture-based methods by identifying a wide range of microorganisms, including those that are difficult to culture, from clinical samples. This is particularly impactful in the Asia-Pacific region, where improving healthcare infrastructure and growing awareness of advanced diagnostic technologies are fueling market growth. The remaining subsegments, including Soil Microbiome and Ecological and Environmental, play a supporting yet crucial role, catering to niche applications. These areas are vital for advancing sustainable agriculture, environmental monitoring, and bioremediation, though their market adoption is more focused on academic research and specific industrial projects. While smaller in revenue contribution today, their future potential is high, especially as global interest in climate change and sustainable practices grows.

Metagenomic Sequencing Market, By Geography

North America

Asia Pacific

Europe

Latin America

Middle East & Africa

The Metagenomic Sequencing market is a specialized and rapidly expanding segment of the life sciences and biotechnology industries. It involves the direct genetic analysis of all genomes within an environmental sample, such as soil, water, or human microbiome. This approach allows researchers to study complex microbial communities without the need for traditional lab cultivation, providing powerful insights into biodiversity, disease diagnosis, drug discovery, and environmental science. The market's growth is fueled by advancements in next-generation sequencing (NGS) technologies, declining sequencing costs, and a heightened focus on personalized medicine and environmental sustainability.

United States Metagenomic Sequencing Market

The United States holds the dominant position in the global metagenomic sequencing market, driven by its robust R&D infrastructure, significant government and private funding, and the presence of leading sequencing technology companies.

Market Dynamics: The U.S. market is characterized by a strong ecosystem of academic and research institutions, pharmaceutical and biotechnology companies, and a well-established healthcare system. Metagenomics is a key tool in ongoing large-scale research projects, such as the NIH's "All of Us" Research Program, which aims to collect diverse genetic data to advance precision medicine. The market is also highly competitive, with major players continuously innovating to improve sequencing platforms and data analysis tools.

Key Growth Drivers: The extensive research in genomics, oncology, and whole-genome sequencing is a primary driver. The growing demand for personalized medicine and targeted therapies is accelerating the use of metagenomic sequencing to understand the role of the human microbiome in disease. Furthermore, significant funding from government agencies and private investment firms for genomics research and infrastructure development is a major catalyst.

Current Trends: A key trend is the integration of metagenomic sequencing into clinical diagnostics for infectious diseases and gastrointestinal disorders. The decreasing cost of sequencing, due to advancements in NGS platforms like Illumina's NovaSeq X series, is making the technology more accessible. There is also a rising focus on microbiome analysis using both 16S rRNA gene amplicons and shotgun metagenomics, providing a more comprehensive understanding of microbial communities.

Europe Metagenomic Sequencing Market

Europe is the second-largest market for metagenomic sequencing, with its growth propelled by strong government support for research, a robust academic community, and increasing applications in clinical diagnostics and biotechnology.

Market Dynamics: The European market benefits from well-funded research initiatives and a collaborative environment among academic institutions and private companies. Countries like Germany, the UK, and France are at the forefront of metagenomics research. The market is also heavily influenced by regulatory frameworks, particularly regarding data privacy and the ethical use of genetic information.

Key Growth Drivers: The availability of research funding and the presence of leading research organizations are significant drivers. The growing use of metagenomics in clinical diagnostics, especially for infectious diseases and in drug discovery, is also fueling market growth. Furthermore, the increasing awareness of the link between the microbiome and human health is expanding the application of metagenomics.

Current Trends: The market is seeing a high adoption of next-generation sequencing technologies. There is a strong focus on using metagenomic sequencing for environmental applications, such as bioprospecting and environmental remediation. The development of portable and user-friendly sequencing devices, such as those from Oxford Nanopore Technologies, is making metagenomics accessible outside of traditional laboratory settings.

Asia-Pacific Metagenomic Sequencing Market

The Asia-Pacific (APAC) region is projected to be the fastest-growing market for metagenomic sequencing, driven by rapid advancements in healthcare infrastructure, increasing research funding, and a large patient population.

Market Dynamics: The APAC market is dynamic and diverse, with countries like China, Japan, South Korea, and India investing heavily in genomics and biotechnology. The region's large and growing patient population, particularly in infectious and chronic diseases, is creating a significant demand for advanced diagnostic and research tools. Government initiatives and strategic collaborations are also playing a crucial role in market expansion.

Key Growth Drivers: The increasing investments in healthcare and research activities are a primary driver. The growing adoption of personalized medicine and the need for accurate diagnostics, particularly for infectious diseases and antimicrobial resistance, are accelerating the use of metagenomic sequencing. Furthermore, the rising awareness of microbial diversity and its impact on health is driving demand from both academic and clinical sectors.

Current Trends: The market is witnessing a high growth rate in the clinical testing segment, driven by the need for precise and non-invasive diagnostic techniques. The integration of next-generation sequencing (NGS), bioinformatics, and AI-driven analysis is a key trend to enhance the accuracy and efficiency of metagenomic profiling. The decline in sequencing costs is also making the technology more accessible to a broader range of end-users in the region.

Latin America Metagenomic Sequencing Market

The Latin American metagenomic sequencing market is in its early stages of development but shows significant potential, driven by growing investments in healthcare and a rising awareness of the link between the microbiome and disease.

Market Dynamics: The market is characterized by a high reliance on imported sequencing technologies and a growing number of research initiatives. Countries like Brazil and Mexico are leading the way, with a focus on applying metagenomics in public health, agriculture, and environmental research. The market faces challenges related to high costs and the need for skilled bioinformatics professionals.

Key Growth Drivers: Advancements in sequencing technologies and a rising demand for personalized medicine are key drivers. The increasing number of research initiatives in microbiome-based therapeutics and the expanding clinical applications in chronic disease management are also contributing to market growth. Supportive government collaborations with international organizations are helping to overcome resource limitations.

Current Trends: The market is witnessing a growing recognition of the microbiome's critical role in human health, which is driving demand for sequencing services. There is a strong interest in using metagenomics for agricultural applications, such as improving crop yields and soil health. Partnerships with international sequencing providers are strengthening the regional market and helping to build local expertise.

Middle East & Africa Metagenomic Sequencing Market

The Middle East & Africa (MEA) region is an emerging market for metagenomic sequencing, with significant growth potential, especially in the Middle East, driven by government investments in healthcare and life sciences research.

Market Dynamics: The MEA market is still in its nascent stage, with a high concentration of research and diagnostic activities in countries like Saudi Arabia and the UAE. The market is characterized by significant government and private funding for large-scale genomics projects aimed at modernizing healthcare systems and improving disease diagnosis.

Key Growth Drivers: The primary drivers are the rising incidence of genetic disorders and infectious diseases. Government initiatives to advance genomic research and precision medicine are also major catalysts. The growing collaboration between international sequencing companies and local academic and research institutions is helping to build regional expertise.

Current Trends: The market is witnessing a strong preference for advanced sequencing technologies for use in diagnostics and drug discovery. There is a growing interest in using metagenomics for a wide range of applications, including disease diagnosis, biomarker discovery, and environmental monitoring. Challenges such as the high cost of sequencing instruments and a shortage of skilled bioinformatics experts are being addressed through strategic initiatives and international partnerships.

Key Players

The "Global Metagenomic Sequencing Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., PerkinElmer, Oxford Nanopore Technologies Ltd., BGI Group, Macrogen Inc., GENEWIZ, Eurofins Scientific, Novogene Corporation. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH DEPLOYMENT METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL METAGENOMIC SEQUENCING MARKET OVERVIEW
  • 3.2 GLOBAL METAGENOMIC SEQUENCING MARKET ESTIMATES AND FORECAST (USD MILLION)
  • 3.3 GLOBAL BIOGAS FLOW METER ECOLOGY MAPPING
  • 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • 3.5 GLOBAL METAGENOMIC SEQUENCING MARKET ABSOLUTE MARKET OPPORTUNITY
  • 3.6 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • 3.7 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY WORKFLOW
  • 3.8 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT AND SERVICES
  • 3.9 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY
  • 3.10 GLOBAL METAGENOMIC SEQUENCING MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
  • 3.11 GLOBAL METAGENOMIC SEQUENCING MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.12 GLOBAL METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • 3.13 GLOBAL METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • 3.14 GLOBAL METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY(USD MILLION)
  • 3.15 GLOBAL METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • 3.16 GLOBAL METAGENOMIC SEQUENCING MARKET, BY EEEE (USD MILLION)
  • 3.17 GLOBAL METAGENOMIC SEQUENCING MARKET, BY GEOGRAPHY (USD MILLION)
  • 3.18 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

  • 4.1 GLOBAL METAGENOMIC SEQUENCING MARKET EVOLUTION
  • 4.2 GLOBAL METAGENOMIC SEQUENCING MARKET OUTLOOK
  • 4.3 MARKET DRIVERS
  • 4.4 MARKET RESTRAINTS
  • 4.5 MARKET TRENDS
  • 4.6 MARKET OPPORTUNITY
  • 4.7 PORTER'S FIVE FORCES ANALYSIS
    • 4.7.1 THREAT OF NEW ENTRANTS
    • 4.7.2 BARGAINING POWER OF SUPPLIERS
    • 4.7.3 BARGAINING POWER OF BUYERS
    • 4.7.4 THREAT OF SUBSTITUTE COMPONENTS
    • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
  • 4.8 VALUE CHAIN ANALYSIS
  • 4.9 PRICING ANALYSIS
  • 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY WORKFLOW

  • 5.1 OVERVIEW
  • 5.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY WORKFLOW
  • 5.3 SAMPLE PROCESSING & LIBRARY PREPARATION
  • 5.4 SEQUENCING
  • 5.5 DATA PROCESSING & ANALYSIS

6 MARKET, BY PRODUCT AND SERVICES

  • 6.1 OVERVIEW
  • 6.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT AND SERVICES
  • 6.3 REAGENTS & CONSUMABLES
  • 6.4 INSTRUMENTS
  • 6.5 SERVICES

7 MARKET, BY TECHNOLOGY

  • 7.1 OVERVIEW
  • 7.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TECHNOLOGY
  • 7.3 SHOTGUN METAGENOMIC SEQUENCING
  • 7.4 16S RRNA SEQUENCING
  • 7.5 METATRANSCRIPTOMICS
  • 7.6 WHOLE-GENOME SEQUENCING & DE NOVO ASSEMBLY

8 MARKET, BY APPLICATION

  • 8.1 OVERVIEW
  • 8.2 GLOBAL METAGENOMIC SEQUENCING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
  • 8.3 DRUG DISCOVERY
  • 8.4 CLINICAL DIAGNOSTICS
  • 8.5 SOIL MICROBIOME
  • 8.6 ECOLOGICAL AND ENVIRONMENTAL

9 MARKET, BY GEOGRAPHY

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 U.S.
    • 9.2.2 CANADA
    • 9.2.3 MEXICO
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 U.K.
    • 9.3.3 FRANCE
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 JAPAN
    • 9.4.3 INDIA
    • 9.4.4 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 BRAZIL
    • 9.5.2 ARGENTINA
    • 9.5.3 REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST AND AFRICA
    • 9.6.1 UAE
    • 9.6.2 SAUDI ARABIA
    • 9.6.3 SOUTH AFRICA
    • 9.6.4 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY DEVELOPMENT STRATEGIES
  • 10.3 COMPANY REGIONAL FOOTPRINT
  • 10.4 ACE MATRIX
    • 10.4.1 ACTIVE
    • 10.4.2 CUTTING EDGE
    • 10.4.3 EMERGING
    • 10.4.4 INNOVATORS

11 COMPANY PROFILES

  • 11.1 OVERVIEW
  • 11.2 ILLUMINA INC
  • 11.3 THERMO FISHER SCIENTIFIC INC
  • 11.4 QIAGEN N.V.
  • 11.5 PERKINELMER
  • 11.6 OXFORD NANOPORE TECHNOLOGIES LTD.
  • 11.7 BGI GROUP
  • 11.8 MACROGEN INC
  • 11.9 GENEWIZ
  • 11.10 EUROFINS SCIENTIFIC
  • 11.11 NOVOGENE CORPORATION

LIST OF TABLES AND FIGURES

  • TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 3 GLOBAL METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 4 GLOBAL METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 5 GLOBAL METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 6 GLOBAL METAGENOMIC SEQUENCING MARKET, BY GEOGRAPHY (USD MILLION)
  • TABLE 7 NORTH AMERICA METAGENOMIC SEQUENCING MARKET, BY COUNTRY (USD MILLION)
  • TABLE 8 NORTH AMERICA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 9 NORTH AMERICA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 10 NORTH AMERICA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 11 NORTH AMERICA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 12 U.S. METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 13 U.S. METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 14 U.S. METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 15 U.S. METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 16 CANADA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 17 CANADA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 18 CANADA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 19 CANADA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 20 MEXICO METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 21 MEXICO METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 22 MEXICO METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 23 MEXICO METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 24 EUROPE METAGENOMIC SEQUENCING MARKET, BY COUNTRY (USD MILLION)
  • TABLE 25 EUROPE METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 26 EUROPE METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 27 EUROPE METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 28 EUROPE METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 29 GERMANY METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 30 GERMANY METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 31 GERMANY METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 32 GERMANY METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 33 U.K. METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 34 U.K. METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 35 U.K. METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 36 U.K. METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 37 FRANCE METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 38 FRANCE METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 39 FRANCE METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 40 FRANCE METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 41 ITALY METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 42 ITALY METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 43 ITALY METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 44 ITALY METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 45 SPAIN METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 46 SPAIN METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 47 SPAIN METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 48 SPAIN METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 49 REST OF EUROPE METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 50 REST OF EUROPE METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 51 REST OF EUROPE METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 52 REST OF EUROPE METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 53 ASIA PACIFIC METAGENOMIC SEQUENCING MARKET, BY COUNTRY (USD MILLION)
  • TABLE 54 ASIA PACIFIC METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 55 ASIA PACIFIC METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 56 ASIA PACIFIC METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 57 ASIA PACIFIC METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 58 CHINA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 59 CHINA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 60 CHINA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 61 CHINA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 62 JAPAN METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 63 JAPAN METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 64 JAPAN METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 65 JAPAN METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 66 INDIA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 67INDIA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 68 INDIA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 69 INDIA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 70 REST OF APAC METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 71 REST OF APAC METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 72 REST OF APAC METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 73 REST OF APAC METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • MILLION)
  • TABLE 74 LATIN AMERICA METAGENOMIC SEQUENCING MARKET, BY COUNTRY (USD MILLION)
  • TABLE 75 LATIN AMERICA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 76 LATIN AMERICA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 77 LATIN AMERICA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 78 LATIN AMERICA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION))
  • TABLE 79 BRAZIL METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 80 BRAZIL METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 81 BRAZIL METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 82 BRAZIL METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 83 ARGENTINA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 84 ARGENTINA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 85 ARGENTINA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 86 ARGENTINA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 87 REST OF LATAM METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 88 REST OF LATAM METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 89 REST OF LATAM METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 90 REST OF LATAM METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 91 MIDDLE EAST AND AFRICA METAGENOMIC SEQUENCING MARKET, BY COUNTRY (USD MILLION)
  • TABLE 92 MIDDLE EAST AND AFRICA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 93 MIDDLE EAST AND AFRICA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 94 MIDDLE EAST AND AFRICA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 95 MIDDLE EAST AND AFRICA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 96 UAE METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 97 UAE METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 98 UAE METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 99 UAE METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 100 SAUDI ARABIA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 101 SAUDI ARABIA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 102 SAUDI ARABIA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 103 SAUDI ARABIA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 104 SOUTH AFRICA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 105 SOUTH AFRICA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 106 SOUTH AFRICA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 107 SOUTH AFRICA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 108 REST OF MEA METAGENOMIC SEQUENCING MARKET, BY WORKFLOW (USD MILLION)
  • TABLE 109 REST OF MEA METAGENOMIC SEQUENCING MARKET, BY PRODUCT AND SERVICES (USD MILLION)
  • TABLE 110 REST OF MEA METAGENOMIC SEQUENCING MARKET, BY TECHNOLOGY (USD MILLION)
  • TABLE 111 REST OF MEA METAGENOMIC SEQUENCING MARKET, BY APPLICATION (USD MILLION)
  • TABLE 112 COMPANY REGIONAL FOOTPRINT